Trials / Conditions / Metastatic Microsatellite Stable Colorectal Carcinoma

Metastatic Microsatellite Stable Colorectal Carcinoma

13 registered clinical trials studyying Metastatic Microsatellite Stable Colorectal Carcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the NCT07363408	City of Hope Medical Center	Phase 1
Recruiting	Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC NCT07281716	Dan Feng	Phase 1 / Phase 2
Recruiting	Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) NCT06654037	National Cancer Institute (NCI)	Phase 1
Withdrawn	Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) NCT05518032	Roswell Park Cancer Institute	Phase 2
Recruiting	Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effective NCT05691491	National Cancer Institute (NCI)	Phase 1 / Phase 2
Active Not Recruiting	Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic NCT05672316	City of Hope Medical Center	Phase 1 / Phase 2
Active Not Recruiting	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Micro NCT05627635	City of Hope Medical Center	Phase 1 / Phase 2
Completed	A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer NCT05130060	Mayo Clinic	Phase 1
Terminated	Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Can NCT04044430	University of California, San Francisco	Phase 1
Withdrawn	Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer NCT03576963	University of Southern California	Phase 1 / Phase 2
Active Not Recruiting	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer NCT03983993	Emory University	Phase 2
Active Not Recruiting	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unres NCT04017650	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer NCT03800602	Emory University	Phase 2